Kornimate/medical-research-clean huggingface dataset:
a multivariate index assay for ovarian cancer risk assessment in women with adnexal mass and high-risk germline variants

Conditions: Adnexal Mass

Summary: the objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the amra blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.


Eligibility criteria:
inclusion criteria: * female patient, 18 years of age or older diagnosed with an ovarian adnexal mass, or in follow-up due to the presence of brca1/2 and other germline dna variants. * patient reviewed, understood, and provided the pi with written informed consent to allow blood specimen to be used for research and release of medical information. exclusion criteria: * patient is less than 18 years of age * patient is not being treated in the u.s.
a phase 2 study to evaluate the safety, pd, pk, and clinical activity of adx-097 in participants with igan, ln or c3g

Conditions: IgA Nephropathy; Lupus Nephritis (LN); C3 (Complement Component 3) Glomerulopathy

Summary: a phase 2 study to evaluate the safety, pharmacodynamics, pharmacokinetics, and clinical activity of adx-097 administered subcutaneously in male and female participants aged 18 years or older with immunoglobulin a nephropathy (igan), lupus nephritis (ln), or complement component 3 glomerulopathy (c3g)


Eligibility criteria:
key inclusion criteria: 1. male or female participants aged ≥18 years. 2. urine protein ≥ 0.75 g/24 hours or upcr ≥ 0.5g/g 3. screening egfr ≥30 ml/min/1.73m2 calculated by the chronic kidney disease epidemiology collaboration creatinine equation (ckd-epi gfr). 4. participants receiving a raas inhibitor must have been on a stable dose (at the maximum recommended dose according to local guidelines or maximum tolerated dose) for at least 12 weeks prior to study day 1 that is projected to remain stable during the study. 5. participants receiving a sodium-glucose cotransporter-2 (sglt2) inhibitor or sparsentan must have been on a stable dose for at least 12 weeks prior to study day 1 that is projected to remain stable during the study. 6. kidney biopsy-proven diagnosis of igan within 52 week; ln within 12 weeks or c3g within 52 weeks of day 1 and with evidence of c3 fragment deposition. key exclusion criteria 1. a ≥50% decline in egfr within 3 months before screening. 2. concomitant significant renal disease other than igan, c3g, or ln. 3. uncontrolled hypertension, defined as systolic blood pressure ≥150 mmhg and/or diastolic blood pressure ≥90 mmhg, despite antihypertensive treatment. 4. kidney, other solid organs, or bone marrow transplantation prior to or expected to occur during the study.
the effect of electroacustimulation on postoperative nausea, vomiting and pain in outpatient plastic surgery patients

Conditions: Postoperative Nausea and Vomiting

Summary: introduction: current rates of postoperative nausea and vomiting (ponv) experienced by outpatient surgery patients are as high as 20-30%. electroacustimulation (eas) therapy has been demonstrated to be effective in controlling these symptoms, but trials identifying their efficacy in the outpatient surgery population are lacking. this study integrates conventional pharmacotherapy with alternative medicine in prevention of ponv. materials and methods: one hundred twenty two patients undergoing surgery procedures at an outpatient surgery center were randomized to two treatment arms. the first arm was standardized pharmacologic ponv prevention typical for patients undergoing outpatient surgery, while the second arm employed the use of reliefband, an fda-approved electroacustimulation (eas) device with pharmacologic treatment to relieve symptoms of ponv and pain. eas is a derivative of acupuncture therapy that uses a small electrical current to stimulate acupuncture points on the human body and is thought to relieve nausea, vomiting and pain. outcomes measured were post-op questionnaires evaluating pain and nausea symptoms, emetic events, the need for rescue medications and the time to discharge.


Eligibility criteria:
inclusion criteria: * undergoing surgery at the university of wisconsin outpatient surgery center exclusion criteria: * pregnancy * currently experiencing menstrual symptoms * cardiac pacemaker * previous experience with acupuncture therapy * pharmacologic treatment for nausea or vomiting in the 24 hours prior to surgery
v503 in chinese girls 9-14 years old versus chinese women 20-26 years old (v503-071)

Conditions: Papillomavirus Infections

Summary: this study aims to demonstrate that a 2-dose regimen of the 9-valent human papillomavirus (9vhpv) vaccine (gardasil™9, v503) induces non-inferior competitive luminex immunoassay (clia) geometric mean titers (gmts) to each of the 9vhpv vaccine types in chinese girls 9 through 14 years of age compared to a 3-dose regimen in chinese women 20 through 26 years of age. the primary hypothesis is that a 2-dose regimen has a non-inferiority margin of 0.67 in the gmt ratio (girls vs. women) for each hpv type.


Eligibility criteria:
the main inclusion and exclusion criteria include but are not limited to the following: inclusion criteria: * is a healthy chinese female. * is not a woman of childbearing potential (wocbp); or is a wocbp who has not had sex with males or has had sex with males and used effective contraception during day 1 through 1 month post last dose. exclusion criteria: * has a history of known prior vaccination with an hpv vaccine. * has a history of severe allergic reaction that required medical intervention. * has a known thrombocytopenia or coagulation disorder that would contraindicate im injections. * has a history of abnormal pap test or external genital wart, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, anal intraepithelial neoplasia, vulvar cancer, vaginal cancer, or anal cancer. * has a history of a positive test for hpv. * has received immune globulin or blood-derived products in the past 6 months or plans to receive any before one month post last dose. * has a history of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, human immunodeficiency virus, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition. * has received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids and certain regimens of systemic corticosteroids.
bacterial colonization on nails covered with a methacrylic coating

Conditions: Bacterial Colonization

Summary: in the research, the investigators will monitor the bacterial colonization of nails coated with a methacrylic coating

it is known that the hand hygiene of healthcare workers is extremely important in order to prevent health-related infections. the effectiveness of hand disinfection can be affected by aspects of hand hygiene such as long nails and fingernail applications. in order to determine whether and to what extent fingernails applied among healthcare workers pose a risk of transmission of potentially pathogenic bacteria, and until what day artificial fingernails are safe in healthcare workers, the investigators will monitor bacterial colonization on nails with uv-cured methacrylic fingernails lamp and compared it with a control group of natural nails without application.

Eligibility criteria:
inclusion criteria: * nurses, doctors and respiratory physiotherapists employed in high-risk wards for patients * healthy nail surface and cuticle exclusion criteria: * subjects with damaged nails or cuticles * operating room staff using surgical hand brushing and staff in general nursing wards.

Keywords: methacrylates nails desinfection transmission of infections
the establish of specific reference ranges for thyroid tests in pregnant women

Conditions: Diseases Pregnancy Thyroid

Summary: a descriptive analysis involving 300 healthy pregnant women to the establish of trimester-specific reference ranges for thyroid tests in pregnant women. 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range.

a descriptive analysis involving 300 healthy pregnant women according nacb to the establish of trimester-specific reference ranges for thyroid tests in pregnant women. according to the selection criteria, 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range. the aim of this study to monitor the change of thyroid function and antibody during the course of pregnancy in those who suffer from various thyroid disorders and normal control.

Eligibility criteria:
inclusion criteria: 1. the people who lived in the city more than five years, aged between 19 and 45, or the single pregnancy women who registered or checked in peking university international hospital would be enrolled. 2. the pregnancy confirmed by the ultrasound or blood hcg test. 3. in order to build a pregnancy reference range of normal pregnant women who must meet the nacb standard. exclusion criteria: 1. the history of thyroid disorders. 2. goiter. 3. oral contraceptives or any drugs affected the function of thyroid. 4. with other chronic autoimmune disease, malignant tumor, blood disease, etc 5. twin pregnancies and multiple pregnancies
hsv-2 suppression to reduce hiv-1 levels in hiv-1 co-infected persons

Conditions: HIV Infections; Herpes Simplex; Sexually Transmitted Diseases

Summary: over 80% of hiv-1 infected persons are also seropositive for hsv-2. increasingly, clinical and epidemiologic evidence show the role of hsv in increasing hiv infectiousness. the evidence suggests that hsv is an important co-factor in hiv transmission. the trial's purpose is to assess the reduction in hiv systemic and mucosal replication associated with valacyclovir for suppression of hsv-2 reactivation. this randomized, double-blind, placebo controlled crossover trial of 20 hiv/hsv-2 co-infected women assessed the effects of daily valacyclovir on hiv-1 levels in blood and body fluids.

conducted in lima peru, 20 hiv-1 and hsv-2 seropositive women with cd4 counts greater than 200 and on no antiretroviral therapy were randomly assigned to receive valacyclovir 500 mg bid or placebo for the first 8 weeks of the study. after these 8 weeks, a 2-week washout period followed, which was then followed by the alternative regimen for 8 weeks.

Eligibility criteria:
inclusion criteria: * greater than 18 years old woman, * documented hiv-1 seropositive, * cd4 count greater than 200, * not on hiv antiretroviral therapy, * hsv-2 seropositive as determined by focus eia (in \>3.5) * not intending to move out of the area for the duration of study participation. * willing and able to:provide independent written informed consent;undergo clinical evaluations;take study drug as directed;adhere to follow-up schedule. * bacterial stds (symptomatic std syndromes or laboratory-confirmed asymptomatic gonorrhea and syphilis) are treated within two weeks of study enrollment and random assignment. exclusion criteria: women who meet any of the following criteria are not eligible for this study: * known history of adverse reaction to valacyclovir, acyclovir or famciclovir; * planned open label use of acyclovir, valacyclovir, or famciclovir * known medical history of seizures * known renal failure, serum creatinine \>2.0mg/dl * hematocrit \< 30 %

Keywords: hiv infection hiv shedding hsv suppression co-infected women reactivation valacyclovir treatment naive
characteristics in post covid-19 patients

Conditions: Coronavirus Infection

Summary: to evaluate pulmonary changes and the results of a cardiopulmonary rehabilitation protocol (cprp) in patients after sars-voc-2 infection. clinical trial type study to be conducted between 2020 and 2024 involving clinical-functional cardiopulmonary imaging and blood transcriptome profile: before cprp (t1), 2 months after cprp (t2) and 1 year later (t3). expected results: a) clinical, image and transcriptome changes; b) clinical-functional improvement after cprp.


Eligibility criteria:
inclusion criteria: * with confirmed diagnosis for sars-cov-2. exclusion criteria: * with any type of simultaneous pneumopathy. * patients with autoimmune disease * people with simultaneous infectious diseases * pregnant women * with degenerative diseases of the nervous system or musculoskeletal system

Keywords: rehabilitation coronavirus
monocyte chemoattractant protein-1 in psoriatic arthritis patients

Conditions: Psoriatic Arthritis

Summary: 1. evaluate serum levels of (mcp-1) in psa with or without cardiovascular affaction . 2. detect subclinical cardiovascular affaction in patients with psa for early diagnosis and management .

psoriatic arthritis (psa) is an autoimmune disease arising from the interply between proinflamatory cytokines \[1\]and external stimuli in genetically predisposed individuals.\[2\] * the disease is chronic and affects the peripheral joints and may include axial skeleton with or without extrarticular manifestations.\[3\] * abnormal activation of the innate and adaptive immune systems contributes to chronic disease processes in both psoriasis and psa .\[4\] the skin and the joints exhibit a prominent lymphocytic infiltrate consisting of activated cd4+ and cd8+ t cells as well as an increase in neutrophil infiltration\[5\]. patients with psa have a higher risk of developing a cardiovascular(cv) events than the general population. this could be attributed to the higher prevalence of traditional cardiovascular risk factors and to the disease characteristics such as systemic inflammation. \[6\] these patients may show asymptomatic cardiomyopathy even in the absence of traditional risk factors \[7\].cardiac dysfunction is associated with a poor prognosis, increased mortality, and affact socioecenomic function of patients therefore, the diagnosis of the cardiac dysfunction in the asymptomatic phase of the disease \[8\] is important for the timely introduction of therapy \[9\].monocyte chemotactic protien1(mcp-1) is a member of chemotactic chemokines(cc) which are secreted by immune effector cells and dysfunctional endothelium \[10\]. * the pivotal function of mcp-1 is to attract monocyte in the arterial wall through increased expression of adhesion molecules on their surface that interacts with endothelium\[11\]. * mcp-1 induce maturation of monocyte in the arterial wall ,which then become specialized macrophage in early atheroma and produce tissue factors supporting coagulation and proinflammatory cytokines such as il-1 and il-6. it affects the functions of the surrounding immune effector cells in locally thickened intima.\[12\] * during active disease in psoriatic skin lesions and synovial tissue, activated monocytes represent the major source of proinflammatory mediators, including the chemokine mcp-1 \[13\]. mcp-1 is thought to be involved in the pathogenesis of oedema and bone erosion in patients with psa \[14\].

Eligibility criteria:
inclusion criteria: * psa patients (age ≥ 18years) who fulfilled the caspar classification criteria\[15\]for psoriatic arthritis exclusion criteria: * psa patients with 1. infection. 2. bone marrow disorders. 3. other autoimmune diseases. 4. diabetes. 5. hypertention . 6. hyperlipidemia. 7. liver diseases. 8. renal diseases.
upper limb unilateral strength training and mirror therapy for chronic stroke patients

Conditions: Stroke

Summary: this is a pilot randomised controlled trial investigating a combination of unilateral strength training (cross-education) and mirror therapy for the rehabilitation of upper limb impairment following a stroke. this study has been conducted as part of a phd qualification at the institute of technology sligo in ireland with all assessments being conducted at the institute and all therapy sessions taking place at the participant's home. the study was conducted in conjunction with sligo university hospital and it attained ethical approval through the relevant university hospital ethics committee.

the study necessitated patients with chronic stroke to perform a strength training programme with their less-affected upper limb. the mirror and strength training group observed the reflection of the training limb in a mirror, the strength training only group exercised without a mirror entirely. patients were referred through hospital health professionals. prior to trial commencement all participants were given comprehensive trial information and provided signed written informed consent. a total of 32 participants were recruited. after a warm-up participants performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb, three days per week, for four weeks. patients received outcome assessment prior to the beginning of the intervention, directly after it and at three-month follow-up assessment. all assessments were carried out by a blinded chartered physiotherapist specialising in stroke rehabilitation. patients were assessed using established outcome measures for upper limb isometric strength, motor function, muscle tone, and self-perceived participation.

Eligibility criteria:
inclusion criteria: chronic stroke diagnosed by a physician at least 6 months prior to study begin discharged from formal rehabilitation services (not receiving outpatient rehabilitation on more than a monthly basis, but may still be in receipt of occupational or language therapy). exclusion criteria: impaired cognition (mini mental state examination (mmse) \< 21) cardiovascular, neurological or musculoskeletal impairments of the upper extremity not related to stroke that would prevent strength training. visual impairments that would interfere with the ability to participate safely in isometric training and observe mirror images.
effects of acbt and blow bottle technique in patients with abdominal surgeries under general anesthesia

Conditions: Abdominal Surgery

Summary: a postoperative pulmonary complication (ppc) is the most common serious complication after abdominal surgery under ga which lead to longer hospital stays and have deleterious outcomes on lung volumes, mucociliary clearance, accumulation of mucus, saliva and cough reflex. chest physiotherapy for airway clearance which includes postural drainage, chest percussion, vibrations, along with these, breathing exercises such acbt and blow bottle technique are recommended to clear secretion which aid in enhancing pulmonary function by effectively mobilizing and eliminating excess bronchial secretions. this study of randomized clinical trial will check the comparative effect of acbt and blow bottle technique in patients with abdominal surgeries under ga by taking a sample of 44 patients through non probability convenience sampling technique. subject of both gender will be included between the age of 30 to 50 years who will undergoes with elective abdominal surgeries under ga (cholecystectomy, hysterectomy ,appendectomy, hemorrhoidectomy) and laparoscopic /open. elective surgeries under spinal anesthesia, emergency surgeries, cardiothoracic surgeries and hemodynamically unstable subjects will be excluded. 22 subjects will receive acbt and other 22 subjects will receive blow bottle technique for 20 minutes duration per session, two sessions per day for a period of 5 days. the status of airway clearance, oxygen saturation and lungs volumes will be measured pre and post intervention on day 1 and at the end of 5th day by using bcss, pulse oximeter and spirometer.


Eligibility criteria:
inclusion criteria: * age 30 to 50 gender: male/female both elective surgeries under general anesthesia (cholecystectomy, hysterectomy ,appendectomy, hemorrhoidectomy) laparoscopic /open both pocs: sputum retention, hypoxemia, impair pulmonary function from the day 0 or immediate after surgery exclusion criteria: * elective surgeries under spinal anesthesia emergency surgeries cardiothoracic surgeries neurological impairment, prolong surgeries psychological impairment head and neck surgeries and vascular surgeries hemodynamically unstable

Keywords: abdominal surgeries active cycle of breathing technique blow bottle technique pulmonary complications,
frailty assessment in elderly patients with acute coronary syndrome

Conditions: Frail Elderly Syndrome; Acute Coronary Syndrome

Summary: frailty is known as an independent risk factor for morbidity and mortality in older cardiac patients . it is an important factor on the cardiologist decision between conservative and invasive treatment in older patient with acute coronary syndrome, and is usually made subjectively by the cardiologist known in the literature as eyeball testing. in this study the investigators will compare the cardiologists eye ball testing to objective frailty assessment based on fried score and edmonton frailty scale.

elderly patients admitted to meir hospital with acute coronary syndrome will be assessed for frailty twice: the first frailty assessment will be a subjective eye ball testing made by the cardiologist, the second assessment will be an objective one based on fried frailty score and edmonton frail scale. the cardiologist will not be aware of the objective frailty assessment result. the eye ball testing will be compared to the objective frailty assessment (fried score and edmonton frailty scale).

Eligibility criteria:
inclusion criteria: * patient admitted to meir hospital with acute coronary syndrome * age: 80 years old and older * eligible for signing an informed concent exclusion criteria: * uncontrolled heart failure ( pulmonary edema or the use of iv diuretics) * cardiogenic shock * fever st elevation myocardial infarction
repeat-dose pharmacokinetics and pharmacodynamics of bortezomib in patients with relapsed multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to characterize the clinical pharmacokinetic and pharmacodynamic profiles of the 2 doses of velcade (bortezomib) for injection. patients who volunteer to participate in the pharmacogenetic portion of the study, an additional blood sample will be collected before the cycle 1 day 1 dose of bortezomib to assess the genotype of drug metabolizing enzymes.


Eligibility criteria:
male and female adult patients 18 years or older with a diagnosis of relapsed multiple myeloma requiring therapy will be eligible for this study. key inclusion criteria include: karnofsky performance status (kps) equal to or greater then 70%, normal liver function tests (aspartate transaminase \[ast\] or alanine transaminase \[alt\] equal to or less then 2 x upper limit of normal \[uln\], total bilirubin equal to or less then 1.5 x uln), hemoglobin equal to or greater then 10 g/dl, platelets equal to greater then 50 x 10 to ninth power/l, and absolute neutrophil count (anc) equal to or greater then 1000/ul; calculated creatinine clearance equal to or greater then 50 ml/min, and normal serum calcium. key exclusion criteria include: patients with significant cardiac disease, equal to or greater then grade 2 neuropathy, active hepatitis, hiv infection, secondary malignancy, poems syndrome, plasma cell leukemia, or who are transfusion-dependent or received extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy within 4 weeks of enrollment will be excluded. patients taking concurrent medications at entry that may act as inducers or inhibitors of cyp 3a4 are excluded. patients receiving thalidomide must discontinue that drug at least 2 weeks prior to enrollment. patients receiving concurrent corticosteroids must have tapered their dose of corticosteroid to to equal to or less then 10 mg/day of prednisone or prednisone equivalent at least 2 weeks prior to enrollment.

Keywords: relapsed multiple myeloma pharmacokinetic pharmacodynamic